Go Pro

Jonathan Wolleben Analyst Performance

Managing Director at Citizens Jmp

Jonathan Wolleben is a stock analyst at Citizens Jmp focused in the medical sector, covering 27 publicly traded companies. Over the past year, Jonathan Wolleben has issued 71 stock ratings, including buy and hold recommendations. While full access to Jonathan Wolleben's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Wolleben's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
120 Last 6 Years
Buy Recommendations
95.65% 110 Buy Ratings
Companies Covered
27 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy95.7%110 ratings
Hold4.3%5 ratings
Sell0.0%0 ratings

Out of 115 total stock ratings issued by Jonathan Wolleben at Citizens Jmp, the majority (95.7%) have been Buy recommendations, followed by 4.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
27 companies

Jonathan Wolleben, an analyst at Citizens Jmp, currently covers 27 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
26 companies
96.3%
Manufacturing
1 company
3.7%

Jonathan Wolleben of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
17 companies
63.0%
MED - DRUGS
8 companies
29.6%
PHARMACEUTICAL PREPARATIONS
2 companies
7.4%

Jonathan Wolleben's Ratings History at Citizens Jmp

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
7/7/2026Downgrade$83.49Hold
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
6/30/2026Boost Price Target$16.07$55.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
6/15/2026Boost Price Target$102.33$146.00Market Outperform
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6/15/2026Reiterated Rating$4.07$11.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
6/11/2026Reiterated Rating$32.99$95.00Market Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5/26/2026Reiterated Rating$41.13$63.00Market Outperform
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
5/19/2026Lower Price Target$6.66$12.00Market Outperform
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
5/14/2026Lower Price Target$57.14$150.00Market Outperform
Altimmune, Inc. stock logo
ALT
Altimmune
5/14/2026Lower Price Target$2.97$11.00Market Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
5/13/2026Lower Price Target$32.08$74.00Market Outperform
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
5/13/2026Lower Price Target$4.63$25.00Market Outperform
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
5/13/2026Lower Price Target$5.05$11.00Market Outperform
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
5/12/2026Boost Price Target$40.08$86.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
5/8/2026Lower Price Target$38.03$95.00Market Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
5/7/2026Boost Price Target$8.65$28.00Market Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5/6/2026Boost Price Target$101.13$137.00Market Outperform
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5/5/2026Initiated Coverage$1.48$9.00Market Outperform
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
5/1/2026Boost Price Target$19.93$55.00Market Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4/29/2026Downgrade$26.66Hold
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
4/28/2026Initiated Coverage$5.12$12.00Market Perform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4/28/2026Boost Price Target$38.62$97.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
4/21/2026Reiterated Rating$94.25$132.00Market Outperform
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3/27/2026Boost Price Target$20.75$47.00Market Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3/26/2026Lower Price Target$16.83$28.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3/17/2026Lower Price Target$90.07$152.00Market Outperform
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
3/10/2026Lower Price Target$62.11$170.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3/2/2026Lower Price Target$41.10$96.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2/27/2026Boost Price Target$98.07$176.00Market Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2/27/2026Lower Price Target$64.75$113.00Market Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/26/2026Boost Price Target$86.85$112.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2/26/2026Lower Price Target$92.21$132.00Market Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
2/24/2026Initiated Coverage$36.10$63.00Market Outperform
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
1/30/2026Downgrade$0.27Market Perform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
1/20/2026Boost Price Target$501.68$745.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
1/8/2026Lower Price Target$53.34$105.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
12/19/2025Boost Price Target$70.28$140.00Market Outperform
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
12/17/2025Boost Price Target$17.98$45.00Market Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
12/12/2025Boost Price Target$67.44$120.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
12/12/2025Boost Price Target$117.62$167.00Market Outperform
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
11/14/2025Boost Price Target$7.61$35.00Market Outperform
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I. (Ad)

Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel

See Jeff Brown and Marc Chaikin's full analysis and next steps here
Savara Inc. stock logo
SVRA
Savara
11/13/2025Lower Price Target$4.12$10.00Market Outperform
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
11/11/2025Set Price Target$115.61$259.00
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
11/11/2025Boost Price Target$115.61$259.00Market Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
11/11/2025Lower Price Target$10.89$28.00Market Outperform
Altimmune, Inc. stock logo
ALT
Altimmune
11/7/2025Lower Price Target$3.94$14.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
11/7/2025Lower Price Target$43.49$108.00Market Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
11/7/2025Boost Price Target$79.63$102.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
11/5/2025Set Price Target$70.97$95.00
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
11/5/2025Set Price Target$444.64$527.00
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
11/5/2025Lower Price Target$6.76$25.00Market Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
11/5/2025Boost Price Target$444.64$527.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
11/5/2025Boost Price Target$70.97$95.00Market Outperform
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
11/3/2025Initiated Coverage$5.03$20.00Market Outperform
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
10/28/2025Set Price Target$123.02$254.00Market Outperform
Savara Inc. stock logo
SVRA
Savara
10/23/2025Boost Price Target$4.11$11.00Market Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
10/15/2025Boost Price Target$6.42$27.00Market Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
10/15/2025Reiterated Rating$11.61Market Perform
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
10/1/2025Boost Price Target$11.69$29.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
9/26/2025Boost Price Target$35.89$143.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
9/25/2025Boost Price Target$96.86$142.00Market Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
9/12/2025Boost Price Target$14.81$28.00Market Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
8/20/2025Boost Price Target$379.55$485.00Market Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
8/15/2025Lower Price Target$4.30$18.00Market Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
8/13/2025Lower Price Target$21.47$52.00Market Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
8/13/2025Boost Price Target$6.88$26.00Market Outperform
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
8/12/2025Lower Price Target$314.00$1,600.00Market Outperform
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
8/11/2025Lower Price Target$26.85$86.00Market Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
8/7/2025Lower Price Target$16.31$87.00Market Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
8/7/2025Boost Price Target$53.42$69.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8/7/2025Set Price Target$59.41$81.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
8/6/2025Boost Price Target$89.85$135.00Market Outperform
Altimmune, Inc. stock logo
ALT
Altimmune
7/10/2025Lower Price Target$4.21$15.00Market Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
7/8/2025Boost Price Target$15.69$27.00Market Outperform
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
6/27/2025Reiterated Rating$2.16$8.00Market Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
6/26/2025Reiterated Rating$62.19$84.00Market Outperform
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
6/26/2025Reiterated Rating$9.06$21.00Market Outperform
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6/24/2025Reiterated Rating$3.16$15.00Market Outperform
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
6/23/2025Reiterated Rating$21.73$89.00Market Outperform
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
5/27/2025Boost Price Target$8.41$21.00Market Outperform
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5/23/2025Reiterated Rating$5.91$19.00Market Outperform
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
5/16/2025Reiterated Rating$13.23$75.00Market Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
5/9/2025Boost Price Target$45.07$76.00Market Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4/24/2025Reiterated Rating$308.00$443.00Market Outperform
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
4/10/2025Initiated Coverage$6.12$38.00Market Outperform
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3/26/2025Set Price Target$5.25$19.00
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/7/2025Reiterated Rating$39.61$58.00Market Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
1/31/2025Initiated Coverage$7.49$26.00Outperform
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
1/31/2025Initiated Coverage$8.77$19.00Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
1/31/2025Boost Price Target$18.06$55.00Market Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
1/31/2025Reiterated Rating$7.96$18.00Market Outperform
Trump’s $250 Bill – See Immediately (Ad)

Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.tc pixel

Watch the free broadcast now and learn where to position your money
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1/10/2025Reiterated Rating$4.14$10.00Market Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
1/10/2025Reiterated Rating$330.62$427.00Market Outperform